A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Subjects With Negative Symptoms of Schizophrenia
Latest Information Update: 30 Aug 2024
At a glance
- Drugs Luvadaxistat (Primary)
- Indications Schizophrenia
- Focus Proof of concept; Therapeutic Use
- Acronyms INTERACT
- Sponsors Takeda Oncology
- 01 Aug 2024 Trial design of INTERACT: a randomized phase 2 study presented at the published in the Schizophrenia Research.
- 21 Jan 2021 Status changed from active, no longer recruiting to completed.
- 08 Jan 2021 According to a Neurocrine Biosciences media release, top-line data expected in 1st Half of 2021.